SELLAS Life Sciences Group, Inc. SLS NASDAQ

SELLAS Life Sciences Group, Inc. (SLS) reported total assets of $78.35M and total liabilities of $7.47M for fiscal year 2025, resulting in total equity of $70.87M.

The company held $71.89M in cash and short-term investments. Total debt stood at $1M, with net debt of $-70.89M. The Debt-to-Equity (D/E) ratio was 0.01 (conservative).

Current ratio is 10.72, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.01, current ratio of 10.72 — balance sheet is strong
• MOAT (52/100) — Total assets $78.35M and equity $70.87M support the company's competitive scale
• VALUE (63/100) — Debt-to-Equity 0.01 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 53/100 with 3/7 criteria passed.

AXSM

Axsome Therapeutics, Inc.

$184.18

+0.07%

KOD

Kodiak Sciences Inc.

$41.98

-6.86%

DAWN

Day One Biopharmaceuticals, Inc.

$21.47

+0.05%

EYPT

EyePoint Pharmaceuticals, Inc.

$14.63

+2.02%

IMMX

Immix Biopharma, Inc.

$10.04

+1.93%

ZURA

Zura Bio Limited

$5.69

-0.52%

PLX

Protalix BioTherapeutics, Inc.

$2.38

+0.85%

SAVA

Cassava Sciences, Inc.

$1.96

-1.76%